Sarepta Therapeutics, Inc.
22.02USD
+1.0800 (+5.16%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 329 | 331 | 443 | 370 | 513 | 612 | 658 | 430 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | -29 | 219 | 361 | 474 | 506 | 338 |
| Operating Income | 13 | 358 | -412 | -103 | 116 | -300 | 162 | 22 |
| Net Income | -5 | 331 | -412 | -51 | 197 | -448 | 159 | 34 |
| EPS (Diluted) | $-0.05 | $2.88 | $-3.93 | $-0.50 | $1.89 | $-4.60 | $1.50 | $0.34 |
Source: SEC filings (EDGAR)